SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia

Verstovšek, Srđan; Komatsu, Norio; Gill, Harinder; Jin, Jie; Lee, Sung‐Eun; Hou, Hsin‐An; Sato, Toshiaki; Qin, Albert; Urbanski, Raymond; Shih, Weichung J.; Zagrijtschuk, Oleh; Zimmerman, Craig; Mesa, Ruben A.

doi:10.2217/fon-2022-0596

Cited by 22 publications

(15 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The new advances may expand the opportunity to use IFN-based therapies in broader cancer indications including advanced metastasis. Ropeginterferon alfa-2b (also known as BESREMi) is a new-generation PEGylated IFN alfa-2b that is administered subcutaneously once every two or more weeks and currently in clinical development for several indications ( 108 – 112 ). In patients with polycythemia vera (PV), a myeloproliferative neoplasm, ropeginterferon alfa-2b provides clinically significant effects at the level of the patient’s bone marrow to selectively inhibit mutation-carrying malignant progenitor cells and increase the ratio of normal versus malignant cells ( 113 – 117 ).…”

Section: Discussionmentioning

confidence: 99%

An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1

Qin¹

2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Interferon-beta (IFN-β), an extracellular cytokine that initiates signaling pathways for gene regulation, has been demonstrated to function as a tumor suppressor protein through lentiviral gene transduction. In this article, I review the relevant previous works and propose a cell cycle-based, tumor suppressor protein-mediated mechanism of anti-cancer surveillance. IFN-β induces a tumor cell cycle alteration that leads to S phase accumulation, senescence entry, and a loss of tumorigenicity in solid tumor cells. IFN-β does not show a significant cell cycle effect in their normal counterparts. Retinoblastoma protein RB1, another tumor suppressor protein, tightly controls the cell cycle and differentiation of normal cells, preventing them from being significantly impacted by the IFN-β effect. The interplay between IFN-β and RB1 acts as a mechanism of cell cycle-based, tumor suppressor protein-mediated anti-cancer surveillance that can selectively suppress solid tumor or proliferating transformed cells from the loss of control leading to cancer. This mechanism has important implications for the treatment of solid tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1

Qin¹

2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…24,89 A phase 3, multicentre, randomized, controlled SURPASS-ET trial (NCT04285086) comparing ropeginterferon alfa-2b with anagrelide in ET patients resistant or intolerant to HC is currently ongoing. 49…”

Section: Ropeginterferonmentioning

confidence: 99%

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon

Ferrer‐Marín,

Hernández‐Boluda,

Alvarez‐Larrán

2024

Br J Haematol

View full text Add to dashboard Cite

SummaryEssential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by an increased risk of vascular complications and a tendency to progress to myelofibrosis and acute leukaemia. ET patients have traditionally been stratified into two thrombosis risk categories based on age older than 60 years and a history of thrombosis. More recently, the revised IPSET‐thrombosis scoring system, which accounts for the increased risk linked to the JAK2 mutation, has been incorporated into most expert recommendations. However, there is increasing evidence that the term ET encompasses different genomic entities, each with a distinct clinical course and prognosis. Moreover, the effectiveness and toxicity of cytoreductive and anti‐platelet treatments differ depending on the molecular genotype. While anti‐platelets and conventional cytoreductive agents, mainly hydroxycarbamide (hydroxyurea), anagrelide and pegylated interferon, remain the cornerstone of treatment, recent research has shed light on the effectiveness of novel therapies that may help improve outcomes. This comprehensive review focuses on the evolving landscape of treatment strategies in ET, with an emphasis on the role of molecular profiling in guiding therapeutic decisions. Besides evidence‐based management according to revised IPSET‐thrombosis stratification, we also provide specific observations for those patients with CALR‐, MPL‐mutated and triple‐negative ET, as well as cases with high‐risk mutations.

show abstract

“…The ongoing global phase 3, multicenter, randomized, controlled SURPASS-ET trial (NCT04285086) (41), and the single-arm EXCEED-ET trial (NCT05482971) in US and Canada (47), are currently evaluating the 250-350-500 mcg dosing scheme. Previous exploratory clinical research and meta-analysis already indicated that interferon therapy could be a safe and effective treatment for ET (42).…”

Section: Clinical Experience Of Ropeginterferon Alfa-2b In Other Mpnsmentioning

confidence: 99%

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Qin¹,

Urbanski²,

Yu³

et al. 2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. However, additional studies may provide rationale for an amended, higher initial dosage and rapid titration. This article is an overview of current and upcoming studies of ropeginterferon alfa-2b in myeloproliferative neoplasms that support the exploration of an amended dosing scheme in order to optimize patient tolerability and efficacy outcomes.

show abstract

SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia

Cited by 22 publications

References 42 publications

An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1

An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Contact Info

Product

Resources

About